Low-Dose Naltrexone (LDN)

Low-dose naltrexone (LDN), typically administered at doses of 1.5-4.5 mg daily (significantly lower than the 50-100 mg doses used for addiction treatment), is being investigated across multiple clinical conditions, though the evidence base remains limited for most applications.

Fibromyalgia

The strongest clinical evidence for LDN exists in fibromyalgia treatment. The INNOVA Study, a 12-month randomized, double-blind, placebo-controlled trial in women with fibromyalgia syndrome, represents the most robust data available as of 2026. While specific results are not detailed in the available evidence, this study followed the earlier FINAL Study, which was a completed Phase 2 trial examining LDN in fibromyalgia patients. A 2026 narrative review highlighted LDN among therapeutic advances in fibromyalgia, suggesting clinical benefit, though the magnitude and consistency of effects require further clarification.

Chronic Pain Management

Beyond fibromyalgia, LDN is being explored for broader chronic pain conditions. A 2026 review in the Journal of Personalized Medicine examined LDN's mechanisms, evidence, and clinical implications in chronic pain management. Currently, a Phase 2 trial is recruiting patients to evaluate LDN's effectiveness in different types of vulvodynia, indicating expanding interest in pain-related applications.

Depression

LDN has been investigated as an adjunctive treatment for major depressive disorder in a randomized, double-blind, placebo-controlled study published in 2026. The study used a hybrid parallel-arm design, though specific efficacy outcomes are not detailed in the available evidence.

Inflammatory Conditions

Clinical interest extends to inflammatory and immune-mediated conditions. A completed Phase 2 trial examined LDN in children with Crohn's disease, suggesting potential applications in inflammatory bowel disease. Additionally, LDN was studied in combination with colchicine for COVID-19 treatment in a completed Phase 2 trial, indicating investigation of its anti-inflammatory properties.

Evidence Limitations

While LDN is being studied across diverse conditions, the clinical evidence remains preliminary for most applications. Many studies are small-scale or early-phase trials. The mechanism of action at low doses appears to differ from high-dose naltrexone, potentially involving modulation of immune function and inflammatory pathways rather than primarily opioid receptor antagonism.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Patients should consult healthcare providers before considering LDN treatment, as it remains investigational for most conditions and may interact with other medications.